Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm characterized by the Philadelphia chromosome (Ph), resulting from a reciprocal translocation t(9;22)(q34;q11) that produces the pathognomonic BCR-ABL1 fusion gene. CML accounts for 15–20% of adult leukemias with an incidence of 1–2 cases per 100,000 person-years, demonstrating a slight male predominance and bimodal age distribution (peaks in 40–60 years and occasionally in children). The disease is critical for board examination because it represents the paradigm of targeted molecular therapy in oncology and has transformed from a uniformly fatal disease to a chronic condition with near-normal life expectancy in the tyrosine kinase inhibitor (TKI) era. Clinical significance encompasses three distinct disease phases (chronic, accelerated, and blastic), each requiring different therapeutic approaches and prognostic counseling.

The BCR-ABL1 fusion protein fundamentally drives CML pathogenesis through constitutive tyrosine kinase activity, creating a self-perpetuating cycle of uncontrolled myeloid proliferation.

The reciprocal translocation t(9;22) joins the ABL1 gene on chromosome 9q34 (normally encoding a tightly regulated tyrosine kinase) with the BCR gene on chromosome 22q11 (encoding a breakpoint cluster region protein). This fusion creates three major isoforms: b3a2 and b2a2 (both producing p210 BCR-ABL1, found in ~95% of CML cases) and e1a2 (producing p190, associated with lymphoid blast crisis). The resulting fusion protein escapes normal cellular regulation mechanisms that typically constrain ABL1 activity, including inhibitory intramolecular interactions and negative feedback loops.

The BCR-ABL1 p210 protein exhibits constitutive (ligand-independent) tyrosine kinase activity, phosphorylating numerous downstream targets on tyrosine residues and triggering multiple dysregulated signaling cascades. Key pathways include: (1) RAS/MAPK pathway activation leading to proliferation signals; (2) PI3K/AKT pathway conferring anti-apoptotic signals; (3) JAK2/STAT5 pathway promoting cytokine-independent survival; (4) CRKL phosphorylation activating downstream proliferative programs; and (5) altered adhesion molecule signaling reducing cell-cell interactions in the bone marrow niche. This multi-pathway activation explains the broad phenotype of BCR-ABL1+ cells, which simultaneously gain proliferative advantage, resist apoptosis, and escape normal growth constraints.

BCR-ABL1 inhibits normal ATM-mediated DNA damage checkpoints and suppresses p53 function, creating a milieu of genomic instability. The fusion protein simultaneously increases oxidative stress through altered mitochondrial function, generating reactive oxygen species (ROS) that further damage DNA. This combination explains why CML cells accumulate additional chromosomal aberrations (secondary cytogenetic abnormalities) as disease progresses, particularly in the accelerated and blastic phases. TKI-resistant mutations (>100 different BCR-ABL1 kinase domain mutations identified) can emerge from this unstable background, complicating long-term disease control.

Normal myeloid progenitors require growth factor stimulation through receptor tyrosine kinases and are dependent on bone marrow stromal interaction for survival. BCR-ABL1-transformed cells become growth factor-independent due to constitutive pathway activation, allowing them to proliferate autonomously. Anti-apoptotic proteins (BCL2, MCL1) are upregulated, while pro-apoptotic signals (p53-mediated) are blunted. Cell cycle checkpoints at G1/S and G2/M are attenuated, permitting transit despite DNA damage or incomplete replication. This explains the massive myeloid expansion characteristic of chronic phase CML, with white blood cell (WBC) counts often exceeding 100,000/μL.

BCR-ABL1+ cells produce increased levels of pro-inflammatory cytokines (IL-6, TNF-α, G-CSF, GM-CSF), creating a permissive bone marrow microenvironment. These cytokines provide both autocrine stimulation and cross-talk with stromal cells, further promoting leukemic cell expansion. Simultaneously, leukemic cells exhibit reduced adhesion to stromal elements, facilitating mobilization and extramedullary hematopoiesis. Increased angiogenesis within the marrow, driven by VEGF and other factors, further supports the leukemic clone.

Transition from chronic to accelerated to blastic phases involves accumulation of additional genetic events: (1) secondary cytogenetic abnormalities (trisomy 8, isochromosome 17q, trisomy 19, monosomy 7, +der(22)); (2) TP53 mutations eliminating apoptosis safeguards; (3) IKZF1 deletion (particularly in lymphoid progression); (4) RUNX1/RUNX1T1 alterations; and (5) MYC amplification. These events progressively select for more aggressive clones with enhanced proliferative capacity and reduced differentiation, ultimately resulting in acute leukemia.

The reciprocal translocation t(9;22) is the initiating and defining cytogenetic event in CML, present in ~95% of cases (the remaining 5% are Ph-negative but BCR-ABL1-positive by molecular testing, or truly Ph-negative BCR-ABL1-negative "atypical CML"). The etiology of the translocation itself remains incompletely understood; there is no proven causative environmental exposure (unlike chronic radiation exposure historically associated with leukemia development post-Chernobyl accident). The translocation likely results from rare erroneous DNA repair mechanisms and is considered a stochastic (random) event requiring no identifiable predisposing factor.

CML shows a slight male predominance (~1.5:1) and classically peaks in the 5th–7th decades of life, though it can present at any age including childhood (rare, <5% of CML cases). No clear hereditary predisposition exists, and CML is not associated with inherited cancer syndromes. The disease appears to arise de novo in nearly all cases with no identified familial clustering.

While not substantiated in modern epidemiology, prior ionizing radiation (atomic bomb exposure in Hiroshima/Nagasaki survivors, occupational exposure in radiologists prior to shielding standards, therapeutic radiation) was historically associated with leukemia, though no specific link to CML has been firmly established in contemporary populations. Chemical exposures (benzene) carry risk for acute myeloid leukemia more than CML. Current understanding suggests CML is fundamentally a random genetic accident rather than an environmentally triggered disease.

Unlike many malignancies, CML has no modifiable risk factors (tobacco, alcohol, diet, obesity) that influence incidence. This reinforces the conception of CML as a purely genetic—rather than epigenetic or lifestyle-driven—disease.

The clinical spectrum of CML spans from asymptomatic patients (discovered incidentally on routine labs) to dramatically symptomatic presentations, depending on disease phase and WBC burden.

When symptoms occur, patients report fatigue and malaise stemming from severe anemia (Hb often 8–10 g/dL) and the metabolic burden of producing >1 trillion myeloid cells daily. Night sweats (often drenching, requiring clothing/sheet changes) result from cytokine production (TNF-α, IL-6) by leukemic cells and reflect increased metabolic rate. Unintentional weight loss occurs through cytokine-driven catabolism and reduced appetite. Low-grade fever (often <38.5°C) is common, mediated by TNF-α and IL-6 rather than infection. These symptoms are non-specific and may be mistakenly attributed to occult infection or malignancy of other organs.

The spleen becomes markedly enlarged (palpable in left upper quadrant, occasionally reaching midline or below) due to extramedullary hematopoiesis—the bone marrow cannot accommodate the massive leukemic expansion, so immature myeloid cells home to spleen and liver. Splenomegaly may cause abdominal fullness, early satiety, or left upper quadrant pain, particularly if splenic infarction occurs. Splenic rupture, while rare, represents a surgical emergency and can occur spontaneously or with minimal trauma in patients with massive splenomegaly.

Similar to splenic involvement, hepatic extramedullary hematopoiesis causes hepatomegaly. Liver function is typically preserved (bilirubin and transaminases remain normal unless complications supervene), distinguishing this from cirrhosis or metastatic disease.

When WBC count exceeds 200,000–300,000/μL, leukostasis may occur—physical obstruction of microvasculature by masses of immature cells, particularly in capillary beds of lungs and central nervous system. Patients report dyspnea on exertion, hypoxia, confusion, altered mental status, or visual disturbances. Leukostasis is more common in acute leukemia than CML, but can occur in CML blast crisis. Additionally, the immense cellular turnover causes hyperuricemia (from purine metabolism) leading to gout attacks or acute kidney injury from uric acid precipitation in renal tubules.

Patients occasionally report bone pain, particularly in long bones and sternum, reflecting intense marrow expansion as normal hematopoietic elements are crowded out by leukemic cells. This can be confused with metastatic bone disease but imaging shows no focal lesions, only generalized marrow hypercellularity.

In the contemporary era, with routine laboratory screening for diverse indications, approximately half of CML patients are discovered incidentally on a CBC obtained for unrelated reasons (pre-operative evaluation, routine health screening, evaluation of other conditions). These patients may have identical disease burden and prognosis to symptomatic patients but represent an opportunity for early detection and potentially superior long-term outcomes.

The diagnostic approach to CML is straightforward and anchored on detecting the BCR-ABL1 fusion, which is pathognomonic for the disease.

The CBC reveals marked leukocytosis (WBC 25,000–300,000/μL; median ~150,000/μL at diagnosis), left-shifted myeloid maturation with bands, metamyelocytes, myelocytes, and promyelocytes present (explaining the term "myeloid leukemia"), and often basophilia and eosinophilia (>5% basophils is a characteristic finding). Anemia is common (Hb 7–11 g/dL), resulting from both bone marrow crowding by leukemic cells and chronic disease. Thrombocytosis is present in ~50% of chronic phase patients (platelet count 400,000–600,000/μL), reflecting increased thrombopoietin production by leukemic cells; conversely, thrombocytopenia suggests accelerated or blastic phase. The peripheral smear shows the spectrum of left-shifted myeloid maturation with relatively preserved myeloid maturation (contrast with acute myeloid leukemia, where blasts predominate).

While not required for diagnosis (molecular confirmation suffices), marrow examination shows hypercellularity (>90%) with left-shifted myeloid maturation and increased myeloid:erythroid ratio (normal M:E ~3:1; in CML often 10:1–20:1 or higher). Marrow biopsy demonstrates dense cellularity with predominantly immature myeloid elements. The marrow is normoblastic and lacks dysplastic features. Blast percentage determines disease phase: chronic phase has <5% blasts, accelerated phase 5–19%, and blastic phase ≥20%. Cytochemical stains demonstrate positive myeloperoxidase (MPO) and Sudan black confirming myeloid differentiation (absent in lymphoid forms).

Conventional karyotype demonstrates the t(9;22)(q34;q11) translocation in ~95% of CML cases. This remains valuable for identifying additional cytogenetic abnormalities (secondary changes) that carry prognostic significance. Spectral karyotyping or fluorescence in situ hybridization (FISH) can confirm t(9;22) in metaphases where standard banding is inconclusive. However, cytogenetics requires dividing cells (often 10–14 days for results) and has lower sensitivity than molecular testing.

Reverse transcription polymerase chain reaction (RT-PCR) is the gold standard for BCR-ABL1 detection and is positive in >99% of CML cases. This test:

The BCR-ABL1/ABL1 ratio at diagnosis typically ranges from 50–90% (meaning BCR-ABL1 represents most transcribed ABL1 in leukemic cells). Isoform determination (b3a2 vs. b2a2) does not currently impact treatment selection but may influence prognosis (p190 historically associated with lymphoid crisis).

BCR-ABL1 transcript levels are monitored via quantitative real-time PCR (qRT-PCR) at **3-month intervals during first year, 6

Contraindicated/cautioned: TKIs are teratogenic — avoid in pregnancy (interferon-alfa is the traditional alternative); nilotinib carries a QT-prolongation/sudden-death boxed warning; ponatinib carries an arterial occlusion boxed warning; dasatinib is avoided with significant pleuropulmonary disease.